1887
Preview this article:
Zoom in
Zoomout

Butyric acid-producing anaerobic bacteria as a novel probiotic treatment approach for inflammatory bowel disease, Page 1 of 1

| /docserver/preview/fulltext/jmm/59/2/141-1.gif

There is no abstract available for this article.
Use the preview function to the left.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.017541-0
2010-02-01
2019-10-24
Loading full text...

Full text loading...

/deliver/fulltext/jmm/59/2/141.html?itemId=/content/journal/jmm/10.1099/jmm.0.017541-0&mimeType=html&fmt=ahah

References

  1. Bajka, B. H., Clarke, J. M., Cobiac, L. & Topping, D. L. ( 2008; ). Butyrylated starch protects colonocyte DNA against dietary protein-induced damage in rats. Carcinogenesis 29, 2169–2174.[CrossRef]
    [Google Scholar]
  2. Breuer, R. I., Soergel, K. H., Lashner, B. A., Christ, M. L., Hanauer, S. B., Vanagunas, A., Harig, J. M., Keshavarzian, A., Robinson, M. & other authors ( 1997; ). Short-chain fatty acid rectal irrigation for left-sided ulcerative colitis: a randomized, placebo-controlled trial. Gut 40, 485–491.[CrossRef]
    [Google Scholar]
  3. Cohen, M. L. ( 2000; ). Changing patterns of infectious disease. Nature 406, 762–767.[CrossRef]
    [Google Scholar]
  4. Danese, S. & Fiocchi, C. ( 2006; ). Etiopathogenesis of inflammatory bowel diseases. World J Gastroenterol 12, 4807–4812.
    [Google Scholar]
  5. Eeckhaut, V., Flahou, B., Romero, C., Van Der Heyden, S., Pasmans, F., Haesebrouck, F., Ducatelle, R. & Van Immerseel, F. ( 2009; ). The anaerobic butyrate-producing strain Butyricicoccus pullicaecorum decreases colonic inflammation and ulceration in a TNBS-induced colitis rat model. In 5th Probiotics, Prebiotics and New Foods Congress, Rome, Italy. http://www.probiotics-prebiotics-newfood.org/pdf/5th_Probiotics_Prebiotics_Newfood.pdf
  6. Flint, H. J., Duncan, S. H., Scott, K. P. & Louis, P. ( 2007; ). Interactions and competition within the microbial community of the human colon: links between diet and health. Environ Microbiol 9, 1101–1111.[CrossRef]
    [Google Scholar]
  7. Geier, M. S., Butler, R. N. & Howarth, G. S. ( 2007; ). Inflammatory bowel disease: current insights into pathogenesis and new therapeutic options; probiotics, prebiotics and synbiotics. Int J Food Microbiol 115, 1–11.[CrossRef]
    [Google Scholar]
  8. Gueimonde, M., Ouwehand, A., Huhtinen, H., Salminen, E. & Salminen, S. ( 2007; ). Qualitative and quantitative analyses of the bifidobacterial microbiota in the colonic mucosa of patients with colorectal cancer, diverticulitis and inflammatory bowel disease. World J Gastroenterol 13, 3985–3989.[CrossRef]
    [Google Scholar]
  9. Hamer, H. M., Jonkers, D., Venema, K., Vanhoutvin, S., Troost, F. J. & Brummer, R. J. ( 2008; ). Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 27, 104–119.
    [Google Scholar]
  10. Hedin, C., Whelan, K. & Lindsay, J. O. ( 2007; ). Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc 66, 307–315.[CrossRef]
    [Google Scholar]
  11. Louis, P. & Flint, H. J. ( 2009; ). Diversity, metabolism and microbial ecology of butyrate-producing bacteria from the human large intestine. FEMS Microbiol Lett 294, 1–8.[CrossRef]
    [Google Scholar]
  12. Mimura, T., Rizzello, F., Helwig, U., Poggioli, G., Schreiber, S., Talbot, I. C., Nicholls, R. J., Gionchetti, P., Campieri, M. & Kamm, M. A. ( 2004; ). Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut 53, 108–114.[CrossRef]
    [Google Scholar]
  13. Ouyang, Q., Tandon, R., Goh, K. L., Ooi, C. J., Ogata, H. & Fiocchi, C. ( 2005; ). The emergence of inflammatory bowel disease in the Asian Pacific region. Curr Opin Gastroenterol 21, 408–413.
    [Google Scholar]
  14. Sokol, H., Pigneur, B., Watterlot, L., Lakhdari, O., Bermudez-Humaran, L. G., Gratadoux, J. J., Blugeon, S., Bridonneau, C., Furet, J. P. & other authors ( 2008; ). Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A 105, 16731–16736.[CrossRef]
    [Google Scholar]
  15. Sokol, H., Seksik, P., Furet, J. P., Firmesee, O., Nion-Larmurier, I., Beaugerie, L., Cosnes, J., Corthier, G., Marteau, P. & Doré, J. ( 2009; ). Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15, 1183–1189.[CrossRef]
    [Google Scholar]
  16. Srinivas, S. R., Prasad, P. D., Umapathy, N. S., Ganapathy, V. & Shekhawat, P. S. ( 2007; ). Transport of butyryl-l-carnitine, a potential prodrug, via the carnitine transporter OCT2 and the amino acid transporter ATB0,+. Am J Physiol Gastrointest Liver Physiol 293, G1046–G1053.[CrossRef]
    [Google Scholar]
  17. Takaishi, H., Matsuki, T., Nakazawa, A., Takada, T., Kado, S., Asahara, T., Kamada, N., Sakuraba, A., Yajima, T. & other authors ( 2008; ). Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 298, 463–472.[CrossRef]
    [Google Scholar]
  18. Thibault, R., Blachier, F., Darcy-Vrillon, B., De Coppet, P., Bourreille, A. & Segain, J. P. ( 2010; ). Butyrate utilization by the colonic mucosa in inflammatory bowel diseases: a transport deficiency. Inflamm Bowel Dis 16 (in press).
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.017541-0
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error